



AXIM BIOTECH

OTC MARKETS: SYMBOL: AXIM

Company Presentation
July 2021



SAFE HARBOR

The statements made by Axim Biotechnologies Inc., in this presentation may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim’s diagnostic products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15 , 2021 and any subsequent quarterly reports on Form 10-Q and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

- AXIM is focused on changing outcomes for Cancer and Covid-19.
- Developing rapid diagnostic tests for the early detection of cancer and therapeutics to suppress metastasis, licensed from Mayo Clinic and Arizona State University.
- National Cancer Institute awarded \$400,000 SBIR phase I Grant.
- Diagnostic expertise allowed us to develop Covid-19 neutralizing antibody tests.



WORLD CLASS SCIENCE TEAM



John Huemoeller II

35 years in financial markets. Investment Banker, Drexel, Smith Barney, Paine Weber.



Sergei Svarovsky, PhD, MBA

Physical Chemist, with NCI, Pfizer
Point-of-Care diagnostic projects Philips, Roche, Bio-Rad,



Douglas Lake, PhD

Associate Professor, ASU and Mayo Clinic.
Molecular and Cellular Immunologist.



Catalina Valencia, J.D.

Extensive management experience with biotech startups-leadership of early-stage Genentech.




Maria Gonzalez-Moa, PhD

Organic Chemist, Fellow NIH. Nanoparticle probes and lateral flow immunoassays. DDTD, Janssen and NanoComposix.



Alim Seit-Nebi, PhD

Molecular Biologist, Scripps Institute, develops our antibody and recombinant proteins and biomarkers




QS0X1

- We discovered Quiescin Sulfhydryl Oxidase 1 (QS0X1) as a Biomarker in tumor derived proteins.
- QS0X1 is over-expressed in multiple human cancers, it is not expressed or minimally expressed in non-malignant tissues.
- We believe QS0X1L is the key to stopping metastasis.

QSOX1 IS A “MASTER REGULATOR” OF DISULFIDE BOND (DSB) FORMATION


The extracellular matrix (ECM) is a collection of proteins secreted by tumor cells and tumor associated fibroblasts. It forms a barrier in and around tumors. [All ECM proteins have disulfide bonds](#). Targeting the enzyme (QSOX1) that makes those disulfide bonds loosens the ECM so that anti-tumor drugs gain access to tumor.



WORLD'S FIRST RAPID DIAGNOSTIC TEST FOR QS0X1-L USING DROP OF BLOOD




Apply drop of blood




Read out result in 10 minutes

Low cost, non-invasive Rapid Diagnostic
Test for point-of-care for multiple cancers


QS0X1 Levels in Different Sample Pools





* 1-2 cm nodule by radiographic imaging (biopsy-confirmed cancer)



SBI-183 inhibits QSOX1L and therefore suppresses tumor growth in mice



86% reduction in tumor size with SBI-183



SPX-009 is 10X more potent than SBI-183:

Triple negative breast cancer




Potency increased
10-fold over SBI-183

Sarcomatoid kidney cancer



Drug Discovery and Development Timeline


SOURCE:FDA




WE ARE HERE

LICENSING COMPOUND FROM MAYO CLINIC SAVED US YEARS OF DEVELOPMENT TIME AND MONEY

The global oncology drug market will reach **\$176 billion** by 2025. The global cancer diagnostics market will grow to **\$249.6 billion** over next 6 years.*




- QSOXL is over expressed in 10 cancers including lung, prostate, breast, brain, kidney, bladder, pancreatic.
- Gives AXIM a pipeline for decades to come.



- Early in the pandemic we decided to utilize our cancer diagnostics expertise to develop rapid tests for COVID-19
- We have now developed 4 different tests to measure neutralizing antibodies (Nabs): LFA for plasma, ELISA, AlphaLisa and LFA for whole blood
- 3 POC studies completed
 - Robustness, analytical performance, clinical agreement study, all validation studies necessary for a 510k FDA application

- Only **NAbs** block binding and entry of the SARS-CoV-2 virus into human host cells.
- However, despite recovering from the disease, not all individuals make high levels of Nabs.
 - Up to 30% do not make measurable levels of NAbs
- The goal of all COVID-19 vaccines is to induce NAbs that block infection.
- Our tests indicate who is protected and who is at risk.
 - Efficacy of Vaccine, am I protected?
 - Durability of immunity, for how long?
 - Do I need a booster shot?
 - When?


LATERAL FLOW POC TEST




- Drop of whole blood
- Rapid: 10 minutes time to result
- Portable
- Inexpensive compared to laboratory tests
- Point-of-Care/At Home Testing/Telemedicine
- Monitors rise and fall in neutralizing antibodies in response to vaccine or natural infection
- Semi-Quantitative

Receiver Operating Characteristic (ROC) Analysis:

Ortho vs SARS-CoV-2 microneutralization



LFA vs SARS-CoV-2 microneutralization



Accuracy

Ortho 85.8%

Axim 97.8%




MANUFACTURING - PARTNERSHIP

Signed
Distribution
and
Manufacturing Agreement

Empowered Diagnostics, Inc.

- Pompano Beach, Florida, USA
- Facility was the largest lateral flow pregnancy test manufacturer in the World
- Tech transfer complete
- EUA filed for Point-Of-Care with FDA
- Filed CE Mark for Europe
- Filed Health Canada
- Capable of manufacturing >7,000,000 tests a week






- We foresaw the supply chain problem early-on
 - China - Expensive
- We make all the biological ingredients – ACE2, spike proteins, control proteins, monoclonals, polystreptavidin
 - Our ACE2 is 10 times more potent and longer shelf life (patent pending)
- Creates additional line of revenue



- Continue developing analogs to SBI-183 for QSOX1L suppression (>200)
- BARDA added grant proposals (March 23) for Nabs tests
- Beginning OTC study – including reader/phone app
- Developing Generation 2 & 3 NAbs rapid diagnostic tests
- Intellectual Property: two more patents are in progress
- Testing various SARS-CoV-2 Variants
- Vaccine study underway


Relative neutralization activity of donor's plasma and serum samples recovered from COVID-19 and immunized with vaccine tested by competitive ELISA with RBD proteins from Wuhan (WU), Brazil (BZ), South-Africa (SA), California (CA), Britain (BT) and Bristol (BS)



Notes:

- 1. Higher bar corresponds to better protection from variant infection
- 2. Specimen VAC-249 is special as it neutralizes all variants equally well (post-Pfizer vaccine)
- 3. VAC-31 and VAC-3283 are most susceptible to Brazilian variant

NOT ALL VACCINES ARE CREATED EQUAL



Vaccine NAbs study with >400 people at ASU & Mayo Clinic

- World Class Science Team
- The ONLY test that matters in a post vaccine world is one that measures neutralizing antibodies.
 - We have the best – Period!!!!!! - Accurate, Fast, Portable, Inexpensive
- Manufacturing agreement - ramping up to 7 million tests a week
 - Expect Revenue in 2nd Qt - 2021
- Strong IP portfolio
 - 5 COVID-19 related patents pending - 4 for cancer, 1 issued
- Strong future pipeline, Cancer, Covid-19 and any other infectious disease



AXIM BIOTECH

For further information, please contact:

John Huemoeller II – CEO

Tel. +1 858-923-4422

info@aximbiotech.com

www.aximbiotech.com